Endocan and Copeptin Serum Levels in Preterm Neonates With Respiratory Distress Syndrome

Tanta University

Status: Enrolling

Conditions: Respiratory Distress Syndrome; Serum; Preterm Neonates; Copeptin; Endocan

Treatments: Diagnostic Test: Serum copeptin; Diagnostic Test: Serum endocan

Study type: Observational

Funder types: Other

Identifiers

NCT07154134

36264PR1296/7/25

Details and patient eligibility

About

This work aims to investigate and compare the levels of serum endocan and serum copeptin on the first day of life and correlate their levels to the severity of respiratory distress in preterm neonates suffering from respiratory distress syndrome.

Full description

Preterm birth continues to be one of the significant challenges in perinatal medicine because of its high incidence of morbidities and mortalities. Its burden on the infant, the family, healthcare systems, and society is enormous.

Endocan is implicated in the recruitment of circulating lymphocytes to inflammatory sites and leukocyte adhesion and activation. Endocan also inhibits leukocyte-endothelial cell adhesion and reduces the excessive leukocyte recruitment into the lungs.

Copeptin, also known as the arginine vasopressin (AVP) associated glycopeptides. AVP is a vasoactive neurohypophysial hormone. It is one of the primary hormones of the hypothalamic-pituitary-adrenal axis, and its primary function is to regulate water and maintain electrolyte homeostasis. The primary stimulus for AVP release is hyperosmolarity.

Enrollment: 40 estimated patients

Sex: All

Ages: 28 to 36 weeks old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Prematurity.
• Gestational age between 28 and 36 weeks.
• Suffering from respiratory distress syndrome.

Exclusion criteria

• Intrauterine growth restriction (IUGR).
• Hypoxic ischemic encephalopathy.
• Multiple congenital anomalies.
• Chromosomal abnormalities.
• Preterm less than 28 weeks.
• Neonates with a maternal history of chorioamnionitis (early sepsis).
• Infant of diabetic mother.
• Prelabor rupture of membranes (PROM)> 2 hours.

Trial design

40 participants in 2 patient groups

Group I

Description:

Neonates with gestational ages between 28 and 34 gestational weeks.

Treatment:

Diagnostic Test: Serum endocan

Diagnostic Test: Serum copeptin

Group II

Description:

Neonates with gestational ages between 34 and 36 gestational weeks.

Treatment:

Diagnostic Test: Serum endocan

Diagnostic Test: Serum copeptin